- Hsieh, Matthew M;
- Bonner, Melissa;
- Pierciey, Francis John;
- Uchida, Naoya;
- Rottman, James;
- Demopoulos, Laura;
- Schmidt, Manfred;
- Kanter, Julie;
- Walters, Mark C;
- Thompson, Alexis A;
- Asmal, Mohammed;
- Tisdale, John F
Ability to accurately attribute adverse events post–gene therapy is required to describe the benefit-risk of these novel treatments. A SCD patient developed myelodysplastic syndrome post-LentiGlobin treatment; we show how insertional oncogenesis was excluded as the cause.
